Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 16 07 2018
revised: 17 09 2018
accepted: 03 11 2018
pubmed: 13 11 2018
medline: 2 11 2019
entrez: 13 11 2018
Statut: ppublish

Résumé

Multiple Myeloma (MM) is an incurable malignancy of terminally differentiated plasma cells, which are predominantly localized in the bone marrow. Myeloid-derived suppressor cells (MDSC) are described to promote MM progression by immunosuppression and induction of angiogenesis. However, their direct role in drug resistance and tumor survival is still unknown. In this study, we performed co-culture experiments of myeloma cells with 5TMM derived MDSC in vitro, leading to increased survival and proliferation of MM cells. Co-culture experiments resulted in MDSC-induced AMPK phosphorylation in MM cells, which was associated with an increase in the anti-apoptotic factors MCL-1 and BCL-2, and the autophagy-marker LC3II. In addition, 5TMM cells inoculated in mice showed a clear upregulation of AMPK phosphorylation in vivo. Targeting the AMPK pathway by Compound C resulted in apoptosis of human myeloma cell lines, primary MM cells and 5TMM cells. Importantly, we observed that the tumor-promoting effect of MDSC was partially mediated by AMPK activation. In conclusion, our data clearly demonstrate that MDSC directly increase the survival of MM cells, partially through AMPK activation, identifying this pathway as a new target in the treatment of MM patients.

Identifiants

pubmed: 30419344
pii: S0304-3835(18)30665-7
doi: 10.1016/j.canlet.2018.11.002
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Map1lc3b protein, mouse 0
Mcl1 protein, mouse 0
Microtubule-Associated Proteins 0
Myeloid Cell Leukemia Sequence 1 Protein 0
Protein Kinase Inhibitors 0
Proto-Oncogene Proteins c-bcl-2 0
Bcl2 protein, mouse 114100-40-2
PRKAA2 protein, human EC 2.7.11.1
AMP-Activated Protein Kinases EC 2.7.11.31
PRKAA1 protein, human EC 2.7.11.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-241

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Kim De Veirman (K)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium. Electronic address: kim.de.veirman@vub.be.

Eline Menu (E)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Ken Maes (K)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Nathan De Beule (N)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Eva De Smedt (E)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Anke Maes (A)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Philip Vlummens (P)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Karel Fostier (K)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Alboukadel Kassambara (A)

Department of Biological Hematology, CHU Montpellier, Montpellier, France; IGH, CNRS, Univ Montpellier, France.

Jérôme Moreaux (J)

Department of Biological Hematology, CHU Montpellier, Montpellier, France; IGH, CNRS, Univ Montpellier, France; University of Montpellier, UFR de Médecine, Montpellier, France.

Jo A Van Ginderachter (JA)

Laboratory of Myeloid Cell Immunology, VIB Inflammation Research Center, 9000, Ghent, Belgium; Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, 1050, Brussels, Belgium.

Elke De Bruyne (E)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Karin Vanderkerken (K)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Els Van Valckenborgh (E)

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH